Pain management in epidermolysis bullosa

Dermatologic Clinics

Volumn 28, Issue 2, 2010, Pages 273-282

  Goldschneider, Kenneth R ^a,b   Lucky, Anne W ^a,b  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

Children; Epidermolysis bullosa; Pain; Pain management; Palliative care; Pediatric pain; Pruritus

Indexed keywords

AMITRIPTYLINE; ANALGESIC AGENT; CANNABINOID; CELECOXIB; CODEINE; DOXEPIN; FENTANYL; FENTANYL CITRATE; GABAPENTIN; HYDROCODONE; HYDROMORPHONE; IBUPROFEN; KETAMINE; KETOROLAC; LIDOCAINE; METHADONE; MORPHINE; NAPROXEN; NARCOTIC AGENT; NARCOTIC ANALGESIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; ONDANSETRON; OXCARBAZEPINE; OXYCODONE; PARACETAMOL; PREGABALIN; TETRAHYDROCANNABINOL; TRAMADOL; UNINDEXED DRUG; VALPROIC ACID;

ADJUVANT THERAPY; ANOREXIA; BEDTIME DOSAGE; CARDIOMYOPATHY; CHRONIC PAIN; CONSTIPATION; DEBRIDEMENT; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; EPIDERMOLYSIS BULLOSA; HEADACHE; HOME CARE; HOSPITAL MANAGEMENT; HUMAN; LOW DRUG DOSE; NAUSEA; NERVE BLOCK; OPIATE ADDICTION; PAIN ASSESSMENT; PAIN THRESHOLD; PALLIATIVE THERAPY; PATIENT CARE PLANNING; PERIOPERATIVE PERIOD; PHYSIOTHERAPY; PRIORITY JOURNAL; PRURITUS; PSYCHOLOGIC ASSESSMENT; QUALITY OF LIFE; REVIEW; RISK FACTOR; SKIN PAIN; SKIN PRURITUS; SYSTEMIC THERAPY; TREATMENT INDICATION; URETHRAL PAIN; WOUND DRESSING;

CHILD; EPIDERMOLYSIS BULLOSA; HUMANS; PAIN; PALLIATIVE CARE;

EID: 77952495887     PISSN: 07338635     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.det.2010.01.008     Document Type: Review

References (52)

1. van Scheppingen C., Lettinga A.T., Duipmans J.C., et al. Main problems experienced by children with epidermolysis bullosa: a qualitative study with semi-structured interviews. Acta Derm Venereol 2008, 88(2):143-150.
2. Fine J.D., Johnson L.B., Weiner M., et al. Assessment of mobility, activities and pain in different subtypes of epidermolysis bullosa. Clin Exp Dermatol 2004, 29(2):122-127.
3. Frew J.W., Martin L.K., Nijsten T., et al. Quality of life evaluation in epidermolysis bullosa (EB) through the development of the QOLEB questionnaire: an EB-specific quality of life instrument. Br J Dermatol 2009, 161:1323-1330. 10.1111/j.1365-2133.2009.09347.x.
4. Mellerio J.E., Weiner M., Denyer J.E., et al. Medical management of epidermolysis bullosa: proceedings of the IInd international symposium on epidermolysis bullosa, Santiago, Chile, 2005. Int J Dermatol 2007, 46(8):795-800.
5. Pain in children: a practical guide for primary care 2008, Humana Press, Totowa (NJ). G.A. Walco, K. Goldschneider (Eds.).
6. Fewtrell M.S., Allgrove J., Gordon I., et al. Bone mineralization in children with epidermolysis bullosa. Br J Dermatol 2006, 154(5):959-962.
7. Perman M.J., Lucky A.W., Heubi J.E., et al. Severe symptomatic hypocalcemia in a patient with RDEB treated with intravenous zoledronic acid. Arch Dermatol 2009, 145(1):95-96.
8. Freeman E.B., Koglmeier J., Martinez A.E., et al. Gastrointestinal complications of epidermolysis bullosa in children. Br J Dermatol 2008, 158(6):1308-1314.
9. Fine J.D., Johnson L.B., Weiner M., et al. Genitourinary complications of inherited epidermolysis bullosa: experience of the national epidermolysis bullosa registry and review of the literature. J Urol 2004, 172(5 Pt 1):2040-2044.
10. Ly L., Su J.C. Dressings used in epidermolysis bullosa blister wounds: a review. J Wound Care 2008, 17(11):482. 484-486, 488 passim.
11. Falabella A.F., Valencia I.C., Eaglstein W.H., et al. Tissue-engineered skin (Apligraf) in the healing of patients with epidermolysis bullosa wounds. Arch Dermatol 2000, 136(10):1225-1230.
12. Fivenson D.P., Scherschun L., Choucair M., et al. Graftskin therapy in epidermolysis bullosa. J Am Acad Dermatol 2003, 48(6):886-892.
13. Sibbald R.G., Zuker R., Coutts P., et al. Using a dermal skin substitute in the treatment of chronic wounds secondary to recessive dystrophic epidermolysis bullosa: a case series. Ostomy Wound Manage 2005, 51(11):22-46.
14. Marini I., Vecchiet F. Sucralfate: a help during oral management in patients with epidermolysis bullosa. J Periodontol 2001, 72(5):691-695.
15. Krajnik M., Zylicz Z., Finlay I., et al. Potential uses of topical opioids in palliative care-report of 6 cases. Pain 1999, 80(1-2):121-125.
16. Twillman R.K., Long T.D., Cathers T.A., et al. Treatment of painful skin ulcers with topical opioids. J Pain Symptom Manage 1999, 17(4):288-292.
17. Watterson G., Howard R., Goldman A. Peripheral opioids in inflammatory pain. Arch Dis Child 2004, 89(7):679-681.
18. Lucky A.W., Palisson F., Mellerio J.E. The IVth international symposium on epidermolysis bullosa, Santiago, Chile, 27-29 September 2007. J Dermatol Sci 2008, 49(2):178-184.
19. Martinez Pardo M.E., Reyes Frias M.L., Ramos Duron L.E., et al. Clinical application of amniotic membranes on a patient with epidermolysis bullosa. Ann Transplant 1999, 4(3-4):68-73.
20. American Academy of Pediatrics, Committee on Drugs. Acetaminophen toxicity in children. Pediatrics 2001, 108(4):1020-1024.
21. Amar P.J., Schiff E.R. Acetaminophen safety and hepatotoxicity-where do we go from here?. Expert Opin Drug Saf 2007, 6(4):341-355.
22. Schechter N.L., Weisman S.J., Rosenblum M., et al. The use of oral transmucosal fentanyl citrate for painful procedures in children. Pediatrics 1995, 95(3):335-339.
23. Lamacraft G., Cooper M.G., Cavalletto B.P. Subcutaneous cannulae for morphine boluses in children: assessment of a technique. J Pain Symptom Manage 1997, 13(1):43-49.
24. Reisfield G.M., Wilson G.R. Rational use of sublingual opioids in palliative medicine. J Palliat Med 2007, 10(2):465-475.
25. Manjushree R., Lahiri A., Ghosh B.R., et al. Intranasal fentanyl provides adequate postoperative analgesia in pediatric patients. Can J Anaesth 2002, 49(2):190-193.
26. Zeppetella G. An assessment of the safety, efficacy, and acceptability of intranasal fentanyl citrate in the management of cancer-related breakthrough pain: a pilot study. J Pain Symptom Manage 2000, 20(4):253-258.
27. Borland M.L., Bergesio R., Pascoe E.M., et al. Intranasal fentanyl is an equivalent analgesic to oral morphine in paediatric Bur patients for dressing changes: a randomised double blind crossover study. Bur 2005, 31(7):831-837.
28. Holroyd K.A., O'Donnell F.J., Stensland M., et al. Management of chronic tension-type headache with tricyclic antidepressant medication, stress management therapy, and their combination: a randomized controlled trial. JAMA 2001, 285(17):2208-2215.
29. Kalso E., Tasmuth T., Neuvonen P.J. Amitriptyline effectively relieves neuropathic pain following treatment of breast cancer. Pain 1996, 64(2):293-302.
30. Rintala D.H., Holmes S.A., Courtade D., et al. Comparison of the effectiveness of amitriptyline and gabapentin on chronic neuropathic pain in persons with spinal cord injury. Arch Phys Med Rehabil 2007, 88(12):1547-1560.
31. Taibjee S.M., Ramani P., Brown R., et al. Lethal cardiomyopathy in epidermolysis bullosa associated with amitriptyline. Arch Dis Child 2005, 90(8):871-872.
32. Magenta P., Arghetti S., Di Palma F., et al. Oxcarbazepine is effective and safe in the treatment of neuropathic pain: pooled analysis of seven clinical studies. Neurol Sci 2005, 26(4):218-226.
33. Silberstein S.D., Collins S.D. Safety of divalproex sodium in migraine prophylaxis: an open-label, long-term study. Long-term safety of depakote in headache prophylaxis study group. Headache 1999, 39(9):633-643.
34. Moore R.A., Straube S., Wiffen P.J., et al. Pregabalin for acute and chronic pain in adults. Cochrane Database Syst Rev 2009, (3). CD007076.
35. Iskedjian M., Bereza B., Gordon A., et al. Meta-analysis of cannabis based treatments for neuropathic and multiple sclerosis-related pain. Curr Med Res Opin 2007, 23(1):17-24.
36. Machado Rocha F.C., Stefano S.C., De Cassia Haiek R., et al. Therapeutic use of Cannabis sativa on chemotherapy-induced nausea and vomiting among cancer patients: systematic review and meta-analysis. Eur J Cancer Care (Engl) 2008, 17(5):431-443.
37. Russo E.B. Cannabinoids in the management of difficult to treat pain. Ther Clin Risk Manag 2008, 4(1):245-259.
38. Bell R.F. Ketamine for chronic non-cancer pain. Pain 2009, 141(3):210-214.
39. Allen K.D., Shriver M.D. Role of parent-mediated pain behavior management strategies in biofeedback treatment of childhood migraines. Behav Ther 1998, 29(3):477-490.
40. Hermann C., Blanchard E.B. Biofeedback in the treatment of headache and other childhood pain. Appl Psychophysiol Biofeedback 2002, 27(2):143-162.
41. Kashikar-Zuck S., Am L. Psychological interventions for chronic pain. Pain in children: a practical guide for primary care 2008, 145-152. Humana Press, Totowa (NJ). G.A. Walco, K. Goldschneider (Eds.).
42. Simons L.E., Claar R.L., Logan D.L. Chronic pain in adolescence: parental responses, adolescent coping, and their impact on adolescent's pain behaviors. J Pediatr Psychol 2008, 33(8):894-904.
43. Gold J.I., Kim S.H., Kant A.J., et al. Effectiveness of virtual reality for pediatric pain distraction during i.v. placement. Cyberpsychol Behav 2006, 9(2):207-212.
44. Kuttner L. Management of young children's acute pain and anxiety during invasive medical procedures. Pediatrician 1989, 16(1-2):39-44.
45. Lin Y.C., Golianu B. Anesthesia and pain management for pediatric patients with dystrophic epidermolysis bullosa. J Clin Anesth 2006, 18(4):268-271.
46. Azizkhan R.G., Denyer J.E., Mellerio J.E., et al. Surgical management of epidermolysis bullosa: proceedings of the IInd international symposium on epidermolysis bullosa, Santiago, Chile, 2005. Int J Dermatol 2007, 46(8):801-808.
47. Mendham J.E. Gabapentin for the treatment of itching produced by burns and wound healing in children: a pilot study. Burns 2004, 30(8):851-853.
48. Jones E.A., Molenaar H.A., Oosting J. Ondansetron and pruritus in chronic liver disease: a controlled study. Hepatogastroenterology 2007, 54(76):1196-1199.
49. Muller C., Pongratz S., Pidlich J., et al. Treatment of pruritus in chronic liver disease with the 5-hydroxytryptamine receptor type 3 antagonist ondansetron: a randomized, placebo-controlled, double-blind cross-over trial. Eur J Gastroenterol Hepatol 1998, 10(10):865-870.
50. Murphy M., Reaich D., Pai P., et al. A randomized, placebo-controlled, double-blind trial of ondansetron in renal itch. Br J Dermatol 2003, 148(2):314-317.
51. Calikoglu E., Anadolu R. Management of generalized pruritus in dominant dystrophic epidermolysis bullosa using low-dose oral cyclosporin. Acta Derm Venereol 2002, 82(5):380-382.
52. Neff G.W., O'Brien C.B., Reddy K.R., et al. Preliminary observation with dronabinol in patients with intractable pruritus secondary to cholestatic liver disease. Am J Gastroenterol 2002, 97(8):2117-2119.